RBC Capital raised the firm’s price target on to $125 from $110 and keeps an Outperform rating on the shares. The company posted a strong start to 2025 with first quarter results well ahead of expectations and a commensurate guidance raise, the analyst tells investors in a research note. Encompass Health (EHC) saw a notable shift in payer mix with Medicare FFS volume outpacing MA for the first time since 2022, RBC adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health price target raised to $130 from $120 at Raymond James
- Encompass Health price target raised to $130 from $110 at Mizuho
- Encompass Health: Strong Performance and Strategic Expansion Drive Buy Rating
- Encompass Health’s Strong Q1 2025 Performance and Strategic Moves Justify Buy Rating
- Encompass Health Stock (EHC) Surges Following Strong Q1 Results and Strategic Expansion Plans